GSA Capital Partners LLP acquired a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 7,137 shares of the medical device company’s stock, valued at approximately $678,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of DXCM. Rockefeller Capital Management L.P. purchased a new stake in shares of DexCom during the first quarter valued at approximately $67,132,000. Point72 Asset Management L.P. increased its stake in shares of DexCom by 429.3% in the first quarter. Point72 Asset Management L.P. now owns 979,175 shares of the medical device company’s stock worth $72,616,000 after buying an additional 794,175 shares during the last quarter. Neuberger Berman Group LLC increased its stake in shares of DexCom by 501.9% in the first quarter. Neuberger Berman Group LLC now owns 637,416 shares of the medical device company’s stock worth $47,271,000 after buying an additional 531,513 shares during the last quarter. Victory Capital Management Inc. increased its stake in shares of DexCom by 67,520.1% in the second quarter. Victory Capital Management Inc. now owns 494,303 shares of the medical device company’s stock worth $46,948,000 after buying an additional 493,572 shares during the last quarter. Finally, Columbus Circle Investors increased its stake in shares of DexCom by 192.3% in the second quarter. Columbus Circle Investors now owns 532,489 shares of the medical device company’s stock worth $50,576,000 after buying an additional 350,339 shares during the last quarter.

A number of analysts recently issued reports on DXCM shares. Stephens restated a “buy” rating and issued a $135.00 price target on shares of DexCom in a research note on Thursday, August 2nd. Bank of America lifted their price target on shares of DexCom from $106.00 to $127.00 and gave the stock a “buy” rating in a research note on Thursday, August 2nd. Canaccord Genuity lifted their price target on shares of DexCom from $105.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday, August 2nd. Jefferies Financial Group lifted their price target on shares of DexCom from $115.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday, August 2nd. Finally, Oppenheimer set a $125.00 price target on shares of DexCom and gave the stock a “buy” rating in a research note on Thursday, August 2nd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have assigned a buy rating and two have given a strong buy rating to the stock. DexCom presently has a consensus rating of “Buy” and a consensus price target of $111.64.

DexCom stock opened at $145.00 on Friday. The firm has a market capitalization of $12.98 billion, a price-to-earnings ratio of -250.91 and a beta of 0.46. The company has a debt-to-equity ratio of 0.69, a current ratio of 4.89 and a quick ratio of 4.62. DexCom, Inc. has a 12 month low of $42.62 and a 12 month high of $148.56.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Wednesday, August 1st. The medical device company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.08. The firm had revenue of $242.50 million during the quarter, compared to the consensus estimate of $205.81 million. DexCom had a negative net margin of 0.65% and a negative return on equity of 7.45%. The firm’s revenue was up 42.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.16) earnings per share. analysts anticipate that DexCom, Inc. will post -0.47 earnings per share for the current fiscal year.

In other DexCom news, VP Patrick Michael Murphy sold 12,500 shares of DexCom stock in a transaction on Friday, August 10th. The shares were sold at an average price of $124.18, for a total value of $1,552,250.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Quentin S. Blackford sold 7,149 shares of DexCom stock in a transaction on Monday, September 10th. The stock was sold at an average price of $143.76, for a total transaction of $1,027,740.24. The disclosure for this sale can be found here. In the last ninety days, insiders sold 207,322 shares of company stock valued at $23,856,914. 1.80% of the stock is currently owned by corporate insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

See Also: What are the Different Types of Leveraged Buyouts?

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.